Healthcare entity
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 5.9 in the same window.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. We currently track 1 Healthcare story that mention MT-125, all published on March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MT-125. Shared-story counts are live from our verified record — not editorial picks.
BioFlorida Showcase
Cornerstone Session presentation on innovation in the regional ecosystem.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
Conference Invitations
Announced invitations to two major South Florida life sciences showcases.
National Partnering
Presented at BioCom California Global Life Science Partnering Conference.
Myosin Therapeutics has been selected to present its first-in-class nanomotor-dependency platform at two major South Florida life sciences conferences in March 2026. The company is advancing MT-125, a dual NMIIA/IIB inhibitor currently in Phase 1/2 trials for glioblastoma, targeting the physical mechanics of cancer cells to bypass traditional resistance.
Source: prnewswire.com · admin (in)
MT-125 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
